On this page
Back to topSionna Therapeutics SION
Sionna Therapeutics listed on Nasdaq on 7 Feb 2025 and is not in the S&P 500. It is worth $134 million. Its board has 12 directors, 9 of them independent. 4 other officers are on file. At 30 Jun 2026, Ra Capital Management was its largest institutional holder, with 21.9% of the company.
- CEO
- Michael Cloonan
- Chair
- Paul J. Clancy
- Listed
- 7 Feb 2025 on Nasdaq
- Headquarters
- Waltham, MA
- Market cap
- $134M
- 19 Nov 2026 close
- Revenue
- -
- No annual report yet
Financials
Sionna Therapeutics' market cap since February 2025
Weekly, up to 13 Nov 2026
| Week ending | Market cap |
|---|---|
| 13 Nov 2026 | $150M |
| 26 Dec 2025 | $1.9B |
Download Sionna Therapeutics' data as JSON, with the weekly market caps in billions of dollars from 7 Feb 2025.
Board and leadership
Board and officers
1 person here also holds roles at other S&P 500 companies.
Board from the proxy filed 27 Apr 2026; officers filed up to 30 Sep 2026
| Name | Title | Since | Independent | Committees | Age |
|---|---|---|---|---|---|
| Directors (12) | |||||
| Paul J. ClancyChairIndependent 路 since 2022 路 Audit, Nominating and Corporate Governance (chair)Visiting Senior Lecturer of Finance at Cornell University's Graduate School of Management and Executive Fellow at Harvard Business SchoolAlso at Incyte | |||||
| Michael CloonanPresident & CEONot independent 路 since 2021 | |||||
| Bruce BoothDirectorIndependent 路 since 2020 路 CompensationGeneral Partner, Atlas VentureOther boards: Kymera Therapeutics | |||||
| Harold Edward FlemingDirectorIndependent 路 since 2024 路 AuditExecutive Vice President of Commercialization, Enavate Sciences GP, LLCOther boards: Upstream Bio and CRISPR Therapeutics AG | |||||
| Lucian IancoviciDirectorIndependent 路 since 2019 路 CompensationManaging Director, TPG Global, LLCOther boards: Rallybio | |||||
| Peter KolchinskyDirector | |||||
| Joshua ResnickDirectorIndependent 路 since 2019Partner, RA Capital Management, L.P.Other boards: PepGen Inc., Aerovate Therapeutics and Vor Biopharma Inc. | |||||
| Marcella K. RuddyDirectorIndependent 路 since 2025 路 Nominating and Corporate GovernanceChief Medical Officer, Tectonic Therapeutic, Inc.Other boards: Upstream Bio | |||||
| Rajeev M. ShahDirector | |||||
| Laurie StelzerDirectorIndependent 路 since 2024 路 Audit (chair), CompensationFormer Chief Financial Officer, Kailera Therapeutics, Inc.Other boards: PMV Pharmaceuticals, Spyre Therapeutics and MBX Biosciences | |||||
| Peter A. ThompsonDirectorIndependent 路 since 2022 路 Nominating and Corporate GovernanceMember, OrbiMed Advisors LLCOther boards: ARS Pharmaceuticals Inc., Corvus Pharmaceuticals and Edgewise Therapeutics | |||||
| Joanne L. VineyDirectorIndependent 路 since 2025 路 Compensation (chair)Chief Executive Officer, Seismic Therapeutic, Inc. | |||||
| Officers (4) | |||||
| Elena RidloffCFO and CBOLast filed 18 Sep 2026 | |||||
| Caroline Stark BeerChief Business OfficerLast filed 6 Jan 2026 | |||||
| Jennifer FitzpatrickCLO and Head of Program MgmtLast filed 18 Sep 2026 | |||||
| Charlotte McKeeCMO and Head of R&DLast filed 18 Sep 2026 | |||||
Owners and trading
Largest institutional holders
Each fund group's share of Sionna Therapeutics. Where a company has several share classes, the share is of its total value.
13F filings for the quarter to 30 Jun 2026
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers sold $81.8 million of stock in 27 sales and made no open-market purchases in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 17 Sep 2026Sale | Peter KolchinskyDirector | $22M |
| 7 Jul 2026Sale | Peter A. ThompsonDirector | $3.9M |
| 6 Jul 2026Sale | Jennifer FitzpatrickCLO and Head of Program Mgmt | $447K |
| 30 Jun 2026Sale | Peter A. ThompsonDirector | $5.3M |
| 27 May 2026Sale | Peter A. ThompsonDirector | $4K |
| 11 May 2026Sale | Peter A. ThompsonDirector | $8.5M |
| 8 May 2026Sale | Peter A. ThompsonDirector | $2.7M |
| 7 May 2026Sale | Peter A. ThompsonDirector | $2.2M |
| 18 Apr 2026Sale | Peter A. ThompsonDirector | $131K |
| 17 Apr 2026Sale | Peter A. ThompsonDirector | $2.3M |
Showing 10 of 27 trades
Timeline
Leadership changes, layoffs and insider sales
20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025
1 departure and 3 appointments of directors and officers and 14 large insider sales in the last two years.
Insider sales of $1 million or more, and the largest tenth of Sionna Therapeutics' insider sales.
Events, newest first
- 17 Sep 2026 Peter Kolchinsky sold $22MDirector
- 9 Sep 2026 Caroline Stark Beer leftChief Business Officer, effective 15 Sep 2026
- 9 Sep 2026 Jennifer Fitzpatrick appointedHead of Program Management, effective 16 Sep 2026
- 9 Sep 2026 Elena Ridloff appointedChief Business Officer, effective 16 Sep 2026
- 9 Sep 2026 Charlotte McKee appointedHead of Research and Development, effective 16 Sep 2026
- 7 Jul 2026 Peter A. Thompson sold $3.9MDirector
- 30 Jun 2026 Peter A. Thompson sold $5.3MDirector
- 11 May 2026 Peter A. Thompson sold $8.5MDirector
Showing 8 of 18 events
| Date | Event | Filing |
|---|---|---|
| 17 Sep 2026 | Peter Kolchinsky sold $22MDirector | Form 4 |
| 9 Sep 2026 | Caroline Stark Beer leftChief Business Officer, effective 15 Sep 2026 | 8-K |
| 9 Sep 2026 | Jennifer Fitzpatrick appointedHead of Program Management, effective 16 Sep 2026 | 8-K |
| 9 Sep 2026 | Elena Ridloff appointedChief Business Officer, effective 16 Sep 2026 | 8-K |
| 9 Sep 2026 | Charlotte McKee appointedHead of Research and Development, effective 16 Sep 2026 | 8-K |
| 7 Jul 2026 | Peter A. Thompson sold $3.9MDirector | Form 4 |
| 30 Jun 2026 | Peter A. Thompson sold $5.3MDirector | Form 4 |
| 11 May 2026 | Peter A. Thompson sold $8.5MDirector | Form 4 |
| 8 May 2026 | Peter A. Thompson sold $2.7MDirector | Form 4 |
| 7 May 2026 | Peter A. Thompson sold $2.2MDirector | Form 4 |
| 17 Apr 2026 | Peter A. Thompson sold $2.3MDirector | Form 4 |
| 16 Apr 2026 | Peter A. Thompson sold $10MDirector | Form 4 |
| 15 Apr 2026 | Peter A. Thompson sold $11MDirector | Form 4 |
| 14 Apr 2026 | Peter A. Thompson sold $2.1MDirector | Form 4 |
| 3 Feb 2026 | Peter A. Thompson sold $1.3MDirector | Form 4 |
| 24 Dec 2025 | Peter A. Thompson sold $1.5MDirector | Form 4 |
| 24 Nov 2025 | Peter A. Thompson sold $4.2MDirector | Form 4 |
| 19 Nov 2025 | Peter Kolchinsky sold $1.9MDirector | Form 4 |
Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months and no quarterly results in its SEC XBRL filings.